跳至主要内容
临床试验/CTRI/2022/05/042364
CTRI/2022/05/042364已完成Unknown

A Prospective, Randomized, Double-Blind, Parallel, Placebo- Controlled Study to Evaluate Efficacy of Lutemax 2020 (Lutein 10 mg & Zeaxanthin Isomers 2 mg) on Vision and Cognitive Performance in Children.

OmniActive Health Technologies Ltd1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2022年5月5日最近更新:
适应症

试验速览

阶段
Unknown
状态
已完成
入组人数
60
试验地点
1
主要终点
Mean change in Macular Pigment Optical Density (MPOD) from Baseline (Day -7 to Day -1) to Visit 5, End of Study Visit (Day 180 + 3 days)

研究概览

简要总结

Extensive exposure to digital devices like laptops, smart phones, etc.is a result of advanced technology in today’s modern world. Especially, the children of 21st century are avid users of technology. The precipitous rise in the use of digital devices has raised concerns about potentially deleterious health effects due to increased screen time and associated exposure to short wavelength blue light. Adverse effects include damage to retina, physical health and cognitive performance. To adapt to this change, a diet-derived, blue-absorbing pigment, composed of the dietary carotenoids lutein (L) and zeaxanthin (Z), which are found in relatively high concentrations in leafy-green vegetables, and along with the Z isomer mesozeaxanthin (MZ), are deposited in rich concentrations in the macular retina. They play an important role in protecting the retina from cumulative damage that can result in visual and cognitive detriments and further progress to Age-related Macular Degeneration (AMD) (Seddon, J.M.et.al., 1994, Richer, S. et.al., 2004) .

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Participant and Investigator Blinded

入排标准

年龄范围
5.00 Year(s) 至 12.00 Year(s)(—)
性别
All

入选标准

  • •1.Children (Male/female) of ≥5 and ≤12 years of age.
  • •2.Participants with BMI equal to or greater than the 5th percentile and less than the 85th percentile for age, gender, and height.
  • •3.Participants with screen time i.e., exposure to digital devices for minimum of 4 hours per day.
  • •4.Participants who agree to maintain their usual dietary habits throughout the trial period.
  • •5.Participants who agree to maintain their usual level of activity throughout the trial period.

排除标准

  • •1.Participants Ë‚ 5 or ˃ 12 years of age.
  • •2.Participants having hypersensitivity or history of allergy to the study product or any of its ingredients.
  • •3.Participants suffering from a metabolic disorder (uncontrolled diabetes, uncontrolled thyroidal condition) and/or from severe chronic disease (cancer, renal failure, HIV, immunodeficiency, hepatic or biliary disorders, uncontrolled cardiac disease) or from a disease found to be inconsistent with the conduct of the study by the investigator.
  • •4.Participants having a current or relevant history of any serious, severe or unstable physical or psychiatric illness or any medical disorder that would make the subject unlikely to fully complete the study or any condition that presents undue risk from the study product or procedures in the opinion of the investigator 5.Participants with a recent history (3 months) of serious infections, injuries and/ or surgeries.

结局指标

主要结局

Mean change in Macular Pigment Optical Density (MPOD) from Baseline (Day -7 to Day -1) to Visit 5, End of Study Visit (Day 180 + 3 days)

时间窗: 6 months

次要结局

  • 1.Mean change in visual processing speed from Baseline (Day-7 to Day-1) to Visit 5, End of Study Visit (Day 180 plus 3 days)(2.Mean change in contrast sensitivity from Baseline (Day -7 to Day -1) to Visit 5, End of Study Visit (Day 180 plus 3 days))

研究者

申办方类型
Pharmaceutical industry-Global

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
1 期
Estudio aleatorizado, multicéntrico, doble ciego y con dosis múltiples para evaluar la eficacia y la seguridad de Pregabalina en comparación con placebo en el tratamiento de pacientes con dolor postoperatorio tras una histerectomía. - N/ATratamiento complementario para el manejo del dolor postoperatorio. (Tras una histerectomía)MedDRA version: 9.1Level: LLTClassification code 10036236Term: Postoperative pain relief
EUCTR2007-000084-24-ESPfizer S.A300
进行中(未招募)
1 期
Estudio, multicéntrico, aleatorizado, doble ciego, fase III de Revlimid (Lenalidomida) versus placebo en pacientes con Síndrome Mielodisplasico de bajo riesgo (IPSS bajo e intermedio-1) con alteración en 5q- y anemia sin necesidades transfusionales. - SINTRA-REVPacientes mayores de 18 años con Síndrome Mielodisplasico de bajo riesgo (IPSS bajo e intermedio-1) con alteración en 5q- y anemia sin necesidades transfusionalesMedDRA version: 12.0Level: LLTClassification code 10067096Term: 5q minus myelodysplastic syndrome
EUCTR2009-013619-36-ESFundación General de la Universidad de Salamanca60
进行中(未招募)
1 期
Estudio multicéntrico, aleatorizado, doble ciego y controlado con vehículo para evaluar la seguridad y la eficacia de SCH 900340 solución al 5% comparado con el vehículo, administrado por vía tópica en el tratamiento de la onicomicosis subungueal distal de la uña del pie. NOTE: The product to be used in the clinical trial is a Topical Solution. Of the choices provided in Section D.3.4 Pharmaceutical Form; per the standard list, Medicated Nail Lacquer was selected at this time.OnicomicosisMedDRA version: 9.1 Level: LLT Classification code 10030338 Term: Onychomycosis
EUCTR2007-004331-27-ESSchering-Plough Research Institute, a Division of Schering Corporation600
进行中(未招募)
不适用
Estudio multicéntrico, aleatorizado, doble ciego y con doble simulación para evaluar dos dosis de adalimumab frente a metotrexato (MTX) en pacientes pediátricos con psoriasis (Ps) en placas crónica A Multi-centre, Randomised, Double-Dummy, Double-Blind Study Evaluating Two Doses of Adalimumab versus Methotrexate (MTX) in Paediatric Subjects with Chronic Plaque Psoriasis (Ps)Psoriasis en placas crónicaMedDRA version: 12.0Level: LLTClassification code 10037153Term: Psoriasis
EUCTR2009-013072-52-ESAbbott GmbH & Co. KG111
进行中(未招募)
不适用
Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo diseñado para demostrar la eficacia y la seguridad del adalimumab como tratamiento de mantenimiento en sujetos adultos que precisan corticosteroides en dosis altas por uveítis intermedia, uveítis posterior opanuveítis no infecciosa activa. - N/Aveítis intermedia, uveítis posterior o panuveítis no infecciosa activaActive Non-infectious Intermediate-, Posterior-, or Pan-uveitisMedDRA version: 12.1Level: LLTClassification code 10022557Term: Intermediate uveitisMedDRA version: 12.1Level: LLTClassification code 10033687Term: PanuveitisMedDRA version: 12.1Level: LLTClassification code 10036370Term: Posterior uveitis
EUCTR2009-016095-68-ESAbbott GmbH & Co. KG250